China’s Mindray Gets U.S. FDA Clearance For New Imaging System
This article was originally published in PharmAsia News
The U.S. FDA has cleared a new type of ultrasound imaging system developed by China's Mindray Medical International. Mindray already had approval from China's State FDA and European regulators for its DC-3 color system used in abdominal, cardiac, endovaginal and OB/GYN treatments. The device is intended to complement its DC-6 and MS systems, but the difference is DC-3 is intended for the low-end markets. (Click here for more
You may also be interested in...
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.